ZIOPHARM Oncology Inc.  

(Public, NASDAQ:ZIOP)   Watch this stock  
Find more results for ZIOP
5.60
+0.10 (1.82%)
Feb 12 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.24 - 5.75
52 week 4.56 - 14.93
Open 5.69
Vol / Avg. 1.89M/3.13M
Mkt cap 746.30M
P/E     -
Div/yield     -
EPS -1.04
Shares 130.89M
Beta 1.91
Inst. own 47%
Feb 24, 2016
Q4 2015 ZIOPHARM Oncology Inc Earnings Release (Estimated) Add to calendar
Jan 13, 2016
ZIOPHARM Oncology Inc at JPMorgan Healthcare Conference
Dec 16, 2015
ZIOPHARM Oncology Inc Conference Call To Discuss Corporate Update and Company's 2016 outlook
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -972.18% -2314.71%
Operating margin -971.96% -3168.17%
EBITD margin - -3134.52%
Return on average assets -49.01% -54.33%
Return on average equity -71.35% -76.37%
Employees 27 -
CDP Score - -

Address

One First Avenue Parris Building 34 Navy Yard Plaza
BOSTON, MA 02129
United States - Map
+1-646-2140700 (Phone)
+1-617-2412855 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is engaged in the acquisition, development and commercialization of a portfolio of cancer therapies through synthetic biology. The Company's pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies. The Company's clinical stage product candidate, Ad-RTS-IL-12 is used with the oral activator veledimex being developed for the treatment of oncology. Ad-RTS-IL-12 in combination with veledimex uses the synthetic biology platform (gene-delivery system) to produce Interleukin-12, or IL-12, a potent, naturally occurring anti-cancer protein. The Company has completed two Phase II studies evaluating Ad-RTS-IL-12 in combination with veledimex, for the treatment of metastatic melanoma, and for the treatment of metastatic breast cancer. The Company is also developing CAR-T Cells (Cytokine products).

Officers and directors

Laurence James Neil Cooper M.D., Ph.D. Chief Executive Officer
Age: 50
Bio & Compensation  - Reuters
Kevin G. Lafond CPA Principal Financial Officer, Chief Accounting Officer, Vice President - Finance, Treasurer
Age: 58
Bio & Compensation  - Reuters
Caesar J. Belbel Chief Operating Officer, Executive Vice President, Chief Legal Officer, Secretary
Age: 55
Bio & Compensation  - Reuters
Murray Brennan Non-Executive Lead Independent Director
Age: 75
Bio & Compensation  - Reuters
Randal J. Kirk Director
Age: 61
Bio & Compensation  - Reuters
James A. Cannon Independent Director
Age: 76
Bio & Compensation  - Reuters
Wyche Fowler Jr., J.D Independent Director
Age: 74
Bio & Compensation  - Reuters
Timothy McInerney Independent Director
Age: 54
Bio & Compensation  - Reuters